Valuation : PYC Therapeutics Limited

Market Cap 2.22B 1.6B 1.37B 1.28B 1.18B 2.22B 153B 15.22B 5.95B 76.96B 6B 5.87B 255B P/E 2026 *
-31.3x
P/E 2027 * -24.5x
Enterprise Value 1.56B 1.12B 962M 901M 825M 1.55B 107B 10.67B 4.17B 53.96B 4.21B 4.12B 179B EV / Sales 2026 *
425x
EV / Sales 2027 * -
Free-Float
70.64%
Yield 2026 *
-
Yield 2027 * -
1 day+4.15%
1 week+5.12%
Current month+32.94%
1 month+33.33%
3 months+63.77%
6 months+51.17%
Current year+36.56%
1 week 2.04
Extreme 2.04
2.28
1 month 1.62
Extreme 1.62
2.28
Current year 1.04
Extreme 1.045
2.28
1 year 0.85
Extreme 0.847
2.28
3 years 0.52
Extreme 0.52
2.28
5 years 0.5
Extreme 0.5
2.28
10 years 0.15
Extreme 0.15
2.28
Manager TitleAgeSince
Chief Executive Officer 42 19/08/2020
Director of Finance/CFO 47 07/07/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 66 18/11/2025
Director/Board Member 42 30/11/2018
Director/Board Member - 22/09/2025
Date Insider Type Main position Quantity % Market Cap.
13/8/26 Free

Chief Executive Officer

4,598,662 0.4676%
13/8/26 Free

Chief Executive Officer

10,477,965 1.0654%
13/8/26 Free

Chief Executive Officer

7,706,503 0.7836%
Change 5-day change 1-year change 3-year change Capi.($)
+4.15%+5.12%+73.85%+289.66% 1.53B
+0.10%+1.59%+1.76%+24.32% 50.96B
+2.65%+3.02%+493.29%+567.32% 46.18B
-0.88%-1.16%+20.58%+87.74% 42.73B
+0.33%+5.26%+39.74%+19.80% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
-1.21%+0.54%+30.32%+135.38% 17.28B
-0.36%-3.95% - - 16.43B
+0.25%+3.31%+11.38%+30.68% 14.73B
+0.44%+2.21%+81.06%+47.92% 14.09B
Average +0.47%+1.29%+85.13%+139.37% 28.04B
Weighted average by Cap. +0.32%+1.16%+105.60%+142.69%

Financials

2026 *2027 *
Net sales 3.67M 2.64M 2.26M 2.12M 1.94M 3.66M 252M 25.1M 9.81M 127M 9.9M 9.69M 420M -
Net income -57.43M -41.31M -35.46M -33.2M -30.4M -57.27M -3.95B -393M -154M -1.99B -155M -152M -6.58B -85.75M -61.68M -52.95M -49.57M -45.39M -85.51M -5.89B -587M -229M -2.97B -232M -227M -9.83B
Net Debt -664M -478M -410M -384M -352M -662M -45.64B -4.55B -1.78B -23B -1.79B -1.76B -76.12B -579M -416M -357M -335M -306M -577M -39.76B -3.96B -1.55B -20.04B -1.56B -1.53B -66.32B
Logo PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
Employees
5
Date Price Change Volume
27/08/26 $2.260 +4.15% 2,391,608
26/08/26 $2.170 +4.33% 1,360,907
25/08/26 $2.080 -0.95% 1,361,994
24/08/26 $2.100 +1.45% 2,019,395
21/08/26 $2.070 -5.91% 2,827,588
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.260AUD
Average target price
3.752AUD
Spread / Average Target
+66.02%

Quarterly revenue - Rate of surprise